Larimar Therapeutics (LRMR) News Today → What is Nvidia’s New $1 Trillion Superproject? (From Weiss Ratings) (Ad) Free LRMR Stock Alerts $7.47 -0.43 (-5.44%) (As of 04:29 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 23 at 4:14 AM | americanbankingnews.comCitigroup Boosts Larimar Therapeutics (NASDAQ:LRMR) Price Target to $14.00May 22 at 2:40 PM | marketbeat.comCitigroup Raises Larimar Therapeutics (NASDAQ:LRMR) Price Target to $14.00Citigroup raised their price target on Larimar Therapeutics from $10.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday.May 22 at 1:25 PM | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Sees Unusually-High Trading VolumeLarimar Therapeutics (NASDAQ:LRMR) Sees Large Volume IncreaseMay 22 at 3:46 AM | americanbankingnews.comLarimar Therapeutics' (LRMR) Market Outperform Rating Reaffirmed at JMP SecuritiesMay 22 at 2:39 AM | markets.businessinsider.comBuy Rating Reaffirmed for Larimar Therapeutics Post FDA Clinical Hold Lift and Positive Drug Trial TrajectoryMay 21 at 4:38 PM | markets.businessinsider.comBuy Rating Affirmed for Larimar Therapeutics as FDA Lifts Hold on Promising Drug NomlabofuspMay 21 at 4:38 PM | msn.comLarimar Therapeutics Advances Friedreich's Ataxia Treatment After FDA Lifts HoldMay 21 at 4:38 PM | msn.comLarimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed DrugMay 21 at 1:29 PM | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Stock Rating Reaffirmed by JMP SecuritiesJMP Securities reissued a "market outperform" rating and issued a $25.00 target price on shares of Larimar Therapeutics in a research note on Tuesday.May 21 at 1:00 PM | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Shares Gap Up to $7.27Larimar Therapeutics (NASDAQ:LRMR) Shares Gap Up to $7.27May 21 at 8:33 AM | markets.businessinsider.comLarimar Therapeutics Says FDA Lifted Partial Clinical Hold For Nomlabofusp In Friedreich's AtaxiaMay 20 at 11:03 PM | markets.businessinsider.comOptimistic Outlook for Larimar Therapeutics’ Nomlabofusp Following FDA’s Lifted Partial HoldMay 20 at 6:02 PM | finance.yahoo.comLarimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s AtaxiaMay 20 at 4:05 PM | globenewswire.comLarimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's AtaxiaMay 16, 2024 | americanbankingnews.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Short Interest Up 7.4% in AprilMay 14, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Trading 10.2% Higher Larimar Therapeutics (NASDAQ:LRMR) Trading Up 10.2%May 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Larimar Therapeutics Backed by Positive Phase 2 Results and Strategic FDA DiscussionsMay 13, 2024 | americanbankingnews.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) to Post FY2026 Earnings of ($2.65) Per Share, William Blair ForecastsMay 10, 2024 | finance.yahoo.comCompanies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In GrowthMay 10, 2024 | markets.businessinsider.comBuy Rating for Larimar Therapeutics Backed by Strong Clinical and Financial OutlookMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Larimar Therapeutics Amid Promising Phase II Data and Strategic OLE Study for FA TreatmentMay 9, 2024 | msn.comLarimar Therapeutics files for $300M mixed shelf offeringMay 9, 2024 | investorplace.comLRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024May 9, 2024 | washingtonpost.comLarimar: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comLarimar Therapeutics Reports First Quarter 2024 Operating and Financial ResultsMay 6, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Shares Up 6%Larimar Therapeutics (NASDAQ:LRMR) Shares Up 6%April 5, 2024 | marketbeat.comEquities Analysts Set Expectations for Larimar Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:LRMR)Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2024 EPS estimates for shares of Larimar Therapeutics in a report issued on Wednesday, April 3rd. Leerink Partnrs analyst J. Park expects that the company will post earnings of ($0.25) per sApril 4, 2024 | marketbeat.comEquities Analysts Set Expectations for Larimar Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:LRMR)Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at Leerink Partnrs issued their FY2026 earnings estimates for shares of Larimar Therapeutics in a research report issued on Wednesday, April 3rd. Leerink Partnrs analyst J. Park forecasts that the company will post earniApril 4, 2024 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Rating of "Buy" from BrokeragesShares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have been given a consensus recommendation of "Buy" by the five brokerages that are covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 12-month target price amonApril 4, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Earns "Outperform" Rating from Leerink PartnrsLeerink Partnrs reiterated an "outperform" rating on shares of Larimar Therapeutics in a report on Wednesday.April 3, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Shares Gap Up to $7.36Larimar Therapeutics (NASDAQ:LRMR) Shares Gap Up to $7.36April 3, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Research Coverage Started at SVB LeerinkSVB Leerink began coverage on shares of Larimar Therapeutics in a research note on Wednesday. They issued an "outperform" rating and a $25.00 price objective on the stock.March 28, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Trading 8.1% Higher Larimar Therapeutics (NASDAQ:LRMR) Trading 8.1% HigherMarch 27, 2024 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Short Interest Up 221.6% in MarchLarimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 1,630,000 shares, an increase of 221.6% from the February 29th total of 506,800 shares. Based on an average trading volume of 570,900 shares, the days-to-cover ratio is currently 2.9 days.March 18, 2024 | marketbeat.comJMP Securities Reiterates Market Outperform Rating for Larimar Therapeutics (NASDAQ:LRMR)JMP Securities reissued a "market outperform" rating and set a $25.00 price objective on shares of Larimar Therapeutics in a research note on Friday.March 18, 2024 | msn.com5 Stocks that Analysts Love in March 2024March 17, 2024 | marketbeat.comShort Interest in Larimar Therapeutics, Inc. (NASDAQ:LRMR) Drops By 18.0%Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) was the target of a large decrease in short interest in February. As of February 29th, there was short interest totalling 506,800 shares, a decrease of 18.0% from the February 14th total of 618,200 shares. Based on an average daily trading volume, of 478,200 shares, the short-interest ratio is currently 1.1 days.March 16, 2024 | finance.yahoo.comLRMR Apr 2024 10.000 callMarch 16, 2024 | markets.businessinsider.comBuy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug NomlabofuspMarch 14, 2024 | investorplace.comLRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023March 14, 2024 | sfgate.comLarimar: Q4 Earnings SnapshotMarch 14, 2024 | benzinga.comRecap: Larimar Therapeutics Q4 EarningsMarch 14, 2024 | finance.yahoo.comLarimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial ResultsMarch 14, 2024 | globenewswire.comLarimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp DevelopmentMarch 12, 2024 | markets.businessinsider.comBuy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich’s AtaxiaMarch 12, 2024 | msn.com3 Best Stocks to Buy Now, 3/12/2024, According to Top AnalystsMarch 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Larimar Therapeutics (LRMR)March 11, 2024 | finance.yahoo.comLarimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s AtaxiaMarch 11, 2024 | globenewswire.comLarimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's AtaxiaMarch 11, 2024 | msn.comLarimar Therapeutics to Present at Global Biopharma Conference in Miami Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address What is Nvidia’s New $1 Trillion Superproject? (Ad)Nvidia recently added $277 billion in market cap … IN ONE DAY. Find out details on these three critical Nvidia partners immediately. LRMR Media Mentions By Week LRMR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LRMR News Sentiment▼0.500.44▲Average Medical News Sentiment LRMR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LRMR Articles This Week▼172▲LRMR Articles Average Week Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Travere Therapeutics News Oculis News Astria Therapeutics News Verve Therapeutics News Adlai Nortye News Entrada Therapeutics News KalVista Pharmaceuticals News Applied Therapeutics News Lexicon Pharmaceuticals News Y-mAbs Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LRMR) was last updated on 5/23/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaThis could mean the end of the U.S dollar…Colonial MetalsElon to Transform U.S. Economy? Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWrite this ticker symbol down…StocksToTrade**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNew Options need New Trading StrategiesNetpicks Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
